Literature DB >> 26123813

Timing of Dynamic NT-proBNP and hs-cTnT Response to Exercise Challenge in Asymptomatic Children with Moderate Aortic Valve Regurgitation or Moderate Aortic Valve Stenosis.

Wadi Mawad1, Sylvia Abadir1, Anne Fournier1, Jean-Luc Bigras1, Daniel Curnier2, Lyes Kadem3, Nagib Dahdah4.   

Abstract

Patients with congenital aortic valve stenosis (AVS) can remain asymptomatic but may develop progressive and often underestimated exercise intolerance. The risk of increased left ventricular (LV) wall stress, irreversible myocardial fibrosis and sudden death in untreated patients warrants earlier intervention. The timing for curative therapy for severe AVS is clear, but optimal timing for moderate stenosis (modAS) is unknown. AVS often coexists with aortic regurgitation, which adds a volume overload to an already pressure-overloaded LV, adding an additional challenge to the estimation of disease severity. We investigated the possible value of N-terminal pro-brain natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin T (hs-cTnT) upon treadmill exercise challenge in children with asymptomatic modAS versus moderate regurgitation (modAR). The aim was to determine optimal timing of peak biochemical response. Blood samples were obtained at rest, and then at 20, 40 and 60 min after peak exercise comparing modAS and modAR to healthy controls. Exercise performance was equivalent in all groups, with no difference for biomarker levels at rest. The increase in NT-proBNP was significant in modAR at 40 min (99.2 ± 48.6 ng/L; p = 0.04) and 60 min into recovery (100.0 ± 53.7 ng/L; p = 0.01), but not in modAS. The increase in hs-cTnT was significant only at 60 min into recovery for modAS and modAR. NT-proBNP and hs-cTnT following exercise challenge are possible discriminant biomarkers of modAR from modAS and controls at 60 min into recovery despite comparable exercise performance. This offers a promising avenue for future stratification of aortic valve disease and optimal timing of intervention.

Entities:  

Keywords:  Aortic regurgitation; Aortic stenosis; Aortic valve disease; Biomarker; High-sensitivity cardiac troponin T; NT-proBNP; Treadmill testing; hs-cTnT

Mesh:

Substances:

Year:  2015        PMID: 26123813     DOI: 10.1007/s00246-015-1225-2

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  26 in total

Review 1.  Brain and other natriuretic peptides: molecular aspects.

Authors:  Marc Vanderheyden; Jozef Bartunek; Marc Goethals
Journal:  Eur J Heart Fail       Date:  2004-03-15       Impact factor: 15.534

2.  Aortic stenosis: even mild disease is significant.

Authors:  Catherine M Otto
Journal:  Eur Heart J       Date:  2004-02       Impact factor: 29.983

3.  An echocardiographic model predicting severity of aortic regurgitation in congenital heart disease.

Authors:  Rebecca S Beroukhim; Dionne A Graham; Renee Margossian; David W Brown; Tal Geva; Steven D Colan
Journal:  Circ Cardiovasc Imaging       Date:  2010-06-25       Impact factor: 7.792

4.  Prognostic usefulness of circulating high-sensitivity troponin T in aortic stenosis and relation to echocardiographic indexes of cardiac function and anatomy.

Authors:  Helge Røsjø; Johanna Andreassen; Thor Edvardsen; Torbjørn Omland
Journal:  Am J Cardiol       Date:  2011-04-27       Impact factor: 2.778

5.  72-h kinetics of high-sensitive troponin T and inflammatory markers after marathon.

Authors:  Johannes Scherr; Siegmund Braun; Tibor Schuster; Charlotte Hartmann; Stefan Moehlenkamp; Bernd Wolfarth; Axel Pressler; Martin Halle
Journal:  Med Sci Sports Exerc       Date:  2011-10       Impact factor: 5.411

6.  Outcome of 622 adults with asymptomatic, hemodynamically significant aortic stenosis during prolonged follow-up.

Authors:  Patricia A Pellikka; Maurice E Sarano; Rick A Nishimura; Joseph F Malouf; Kent R Bailey; Christopher G Scott; Marion E Barnes; A Jamil Tajik
Journal:  Circulation       Date:  2005-06-13       Impact factor: 29.690

7.  Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study.

Authors:  Justin T Saunders; Vijay Nambi; James A de Lemos; Lloyd E Chambless; Salim S Virani; Eric Boerwinkle; Ron C Hoogeveen; Xiaoxi Liu; Brad C Astor; Thomas H Mosley; Aaron R Folsom; Gerardo Heiss; Josef Coresh; Christie M Ballantyne
Journal:  Circulation       Date:  2011-03-21       Impact factor: 29.690

8.  Natriuretic peptide as an adjunctive diagnostic test in the acute phase of Kawasaki disease.

Authors:  Nagib Dahdah; Ana Siles; Anne Fournier; Jocelyne Cousineau; Edgard Delvin; Claire Saint-Cyr; Linda Spiegelblatt; Yvette Bonny; Michèle Vartian; Martine Montigny
Journal:  Pediatr Cardiol       Date:  2009-04-14       Impact factor: 1.655

9.  Analytical performance of the N terminal pro B type natriuretic peptide (NT-proBNP) assay on the Elecsys 1010 and 2010 analysers.

Authors:  P O Collinson; S C Barnes; D C Gaze; G Galasko; A Lahiri; R Senior
Journal:  Eur J Heart Fail       Date:  2004-03-15       Impact factor: 15.534

Review 10.  Science review: natriuretic peptides in critical illness.

Authors:  Rochus Witthaut
Journal:  Crit Care       Date:  2004-06-17       Impact factor: 9.097

View more
  1 in total

1.  On Left Ventricle Stroke Work Efficiency in Children with Moderate Aortic Valve Regurgitation or Moderate Aortic Valve Stenosis.

Authors:  M Asaadi; W Mawad; A Djebbari; Z Keshavardz-Motamed; N Dahdah; L Kadem
Journal:  Pediatr Cardiol       Date:  2021-08-06       Impact factor: 1.655

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.